ACT with tumor infiltrating lymphocytes in patients with metastatic melanoma has demonstrated durable objective responses, especially when a prior lymphodepletion regimen was used.3, 4 A drawback of these ACT studies was the requirement of systemic IL-2 administration, which induced significant side-effects such as capillary leakage.5 This evidence concerns the gene IL2 and neoplasm.